Dr. Ashish Kamat

Dr. Ashish M. Kamat is an Endowed Professor of Urologic Oncology (Surgery) and Cancer Research, and the Director of the Bladder Cancer Support Program at University of Texas MD Anderson Cancer Center in Houston. He is the founding President of the International Bladder Cancer Group (IBCG) and serves as the Associate Cancer Center Director at the RFHNH Hospital in Mumbai. Dr. Kamat specializes in genitourinary cancers, with a particular focus on immunotherapy for urothelial cancers. He has led numerous research efforts and clinical trials in this field, resulting in over 610 publications in prestigious journals, textbooks and news articles.


Dr. Kamat's influence extends globally through his leadership in organizations such as the IBCG, the International Bladder Cancer Network (IBCN), and the Société Internationale d'Urologie (SIU). He actively contributes to organizations including the American Urologic Association (AUA), the Society of Urologic Oncology (SUO), American Society of Clinical Oncology (ASCO), and European Association of Urology (EAU), having served on their boards and played pivotal roles in organizing national and international meetings. Additionally, Dr Kamat serves on advisory boards for research groups, healthcare systems, industry think tanks, and biotech innovators.


A dedicated educator, Dr. Kamat served as Fellowship Director at MD Anderson (2005-2016) and continues to mentor students, residents, fellows, and international visiting scholars, including via the AUA USMART Program. He serves on editorial boards of leading journals including European Urology Oncology, Urologic Oncology, Journal of Urology, Expert Reviews, and leads UroToday’s Bladder Cancer Center of Excellence.